Abacavir/lamivudine: Phase III

In an open-label Phase III trial, 49% (50/102) of patients given once-daily abacavir/lamivudine plus Viread tenofovir had a virologic non-response after

Read the full 216 word article

How to gain access

Continue reading with a
two-week free trial.